As of 2025-07-14, the Intrinsic Value of GT Biopharma Inc (GTBP) is -14.79 USD. This GTBP valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.23 USD, the upside of GT Biopharma Inc is -763.28%.
Based on its market price of 2.23 USD and our intrinsic valuation, GT Biopharma Inc (GTBP) is overvalued by 763.28%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -14.79 - -14.79 | -14.79 | -763.28% |
| P/E | (74.31) - (143.42) | (87.56) | -4026.6% |
| DDM - Stable | (19.85) - (60.44) | (40.15) | -1900.4% |
| DDM - Multi | (19.06) - (47.05) | (27.36) | -1326.7% |
| Market Cap (mil) | 8.80 |
| Beta | 0.52 |
| Outstanding shares (mil) | 3.95 |
| Enterprise Value (mil) | 6.43 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.42% |
| Cost of Debt | 5.00% |
| WACC | 7.54% |